| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | OSI-930 | GDSC1000 | pan-cancer | AAC | -0.0027 | 0.9 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.0026 | 0.9 |
| mRNA | AZD8055 | GDSC1000 | pan-cancer | AAC | 0.0026 | 0.9 |
| mRNA | embelin | GDSC1000 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | -0.0025 | 0.9 |
| mRNA | HG-6-64-1 | GDSC1000 | pan-cancer | AAC | -0.0025 | 0.9 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.0025 | 0.9 |
| mRNA | BYL-719 | CTRPv2 | pan-cancer | AAC | 0.003 | 0.9 |
| mRNA | B02 | CTRPv2 | pan-cancer | AAC | -0.0025 | 0.9 |
| mRNA | SKI-II | CTRPv2 | pan-cancer | AAC | 0.0025 | 0.9 |